|
| G1-G2 (1994-2005) N = 200 mOS (months) p value | G3 (2006-2011) N = 201 mOS (months [CI]) p value | ||
| General condition (WHO) |
|
|
|
|
| ≥2 | 10.3 | 0.9 | 5.78 [1.12 - 10.44] | <0.0001 |
| <2 | 17.8 |
| 24.74 [19.87 - 29.6] |
|
| Absence of initial tumor complication |
|
|
|
|
| Yes | - |
| 28.32 [21.83 - 34.8] | 0.038 |
| No |
|
| 19.84 [15.25 - 24.43] |
|
| Metastases |
|
|
|
|
| Metachronous | 14.7 | 0.28 | 35.97 [29.53 - 42.42] | <0.0001 |
| Synchronous | 11.4 |
| 13.37 [10.73 - 16] |
|
| Localisation of metastases |
|
|
|
|
| Liver | 17.6 | 0.3 | 10.65 [12.11 - 21.19] | <0.0001 |
| Lung | 18 |
| 29.04 [5.41 - 52.67] |
|
| Peritoneum | 33.2 |
| 12.22 [9.58 - 14.86] |
|
| Ovary | 18.2 |
| 15.64 [12.55 - 18.72] |
|
| Normal liver function tests (%) |
|
|
|
|
| Yes | 20.5 | <0.001 | 24.87 [21.12 - 28.6] | 0.007 |
| No | 12.3 |
| 10.45 [3.6 - 17.29] |
|
| Normal initial level of CEA (%) |
|
|
|
|
| Yes | 24.5 | 0.01 | 33.67 [26.6 - 40.7] | <0.0001 |
| No | 15.1 |
| 18.66 [13.36 - 24] |
|
| Surgery of the primary tumor |
|
|
|
|
| Yes | - |
| 15.05 [11.118.9] | 0.001 |
| No |
|
| 5.88 [4.49 - 7.27] |
|
| Surgery of liver metastases |
|
|
|
|
| Yes | 40.7 | 0.05 | 25.2 [15.69 - 34.71] | 0.016 |
| No | 15.1 |
| 20.27 [13.02 - 27.52] |
|
| ORR after 3 cycles of first line CT |
|
|
|
|
| Yes | 15.3 | <0.0005 | 29 [21.86 - 36.2] | 0.034 |
| No | 13.3 |
| 20.2 [13.8 - 26.7] |
|
| Folfiri ± bevazicumab as third line CT | - |
| 22.75 [-] | 0.031 |